Beckley Psytech grows team with new Clinical Operations and Communications hires

Ruth joins the team from Achilles Therapeutics, a biopharmaceutical company developing novel cancer immunotherapies targeting neoantigens, where she was Director of Clinical Operations and held functional responsibility for the Global Clinical Operations team. Before that, Ruth was Director of OUS Clinical Operations at Aiummune Therapeutics, a biopharmaceutical company developing and bringing new treatments to people with food-mediated conditions and potentially life-threatening food allergies. Throughout her career, Ruth has overseen clinical trials from Phase I to Phase IV across multiple disease areas, including HIV/AIDS, oncology, and pulmonary diseases. With over 25 years of experience in clinical trial planning and execution, Ruth brings with her a wealth of expertise that will be vital as Beckley Psytech looks forward to scaling its clinical pipeline in the coming months and years.

Charlotte assumes the role of Communications Lead from Healx, an AI-powered biotechnology company looking to discover new treatments for rare diseases. In her role as Director of Strategic Alignment and Communications at Healx, Charlotte oversaw all external and internal communications and helped build the company’s corporate reputation in global markets. She also supported the Executive Team with strategic planning and execution. Prior to her role at Healx, Charlotte held communication responsibilities at both Google and DeepMind, where she worked specifically on communicating their health-related research and products to a range of audiences, including patients and policy-makers. During her career, Charlotte has gained significant experience in the healthtech and biotech space and she will now be tasked with leveraging that knowledge to consolidate Beckley Psytech’s position as one of the leading voices in the psychedelic medicine space.

Ruth and Charlotte join the team at an exciting period for the company, with a Phase 1 study of their innovative formulation of 5-MeO-DMT, BPL-003, nearing completion, and their appointments strengthen Beckley Psytech’s operational and clinical expertise ahead of its next stage of growth.

Commenting on her appointment, Ruth Bateson said: “I am delighted to have joined Beckley Psytech at such an exciting time in this groundbreaking area of medicine. It is incredible to be part of an organisation with such a strong sense of purpose and clear focus as we work towards making a meaningful difference to patients lives by integrating safe and effective psychedelic treatments into mainstream medical practice ”

Charlotte Chorley also said: “I have long admired Beckley Psytech’s incredible mission and vision for the future of psychedelic medicine, and I am very proud to now be working to deliver that vision to people in need. I look forward to collaborating with the world-leading team at Beckley Psytech in order to translate our scientific and clinical research into much-needed treatments for patients.”